Abivax S.A.

Clinical-stage biotech developing oral immunomodulators for chronic inflammatory diseases. Lead asset obefazimod (ABX464) is a first-in-class miR-124 enhancer in Phase 3 ABTECT for moderate-to- severely active ulcerative colitis, with positive 8-week induction data reported in Q3 2025 and 44-week maintenance topline expected in Q2 2026 ahead of a planned NDA in 2H 2026.